Comparison of the 4 drugs licensed for use in MCL
| Treatment . | No. patients . | ORR . | CR . | Median DOR (months) . | Median PFS (months) . | Median OS (months) . |
|---|---|---|---|---|---|---|
| Ibrutinib16 | 111 | 68% | 21% | 17.5 | 13.9 | Not reached |
| Bortezomib49 | 155 | 33% | 8% | 9.2 | 6.5 | 23.5 |
| Lenalidomide51 | 134 | 28% | 8% | 16.6 | 4 | 19 |
| Temsirolimus50 | 54* | 22% | 2% | 7.1 | 4.8 | 12.8 |
| Treatment . | No. patients . | ORR . | CR . | Median DOR (months) . | Median PFS (months) . | Median OS (months) . |
|---|---|---|---|---|---|---|
| Ibrutinib16 | 111 | 68% | 21% | 17.5 | 13.9 | Not reached |
| Bortezomib49 | 155 | 33% | 8% | 9.2 | 6.5 | 23.5 |
| Lenalidomide51 | 134 | 28% | 8% | 16.6 | 4 | 19 |
| Temsirolimus50 | 54* | 22% | 2% | 7.1 | 4.8 | 12.8 |
ORR, overall response rate.
Results are presented for temsirolimus 175/75 mg dose group.